[{"orgOrder":0,"company":"Hartford Hospital","sponsor":"Merck & Co","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"U.S.A","productType":"Miscellaneous","year":"2010","type":"Inapplicable","leadProduct":"Alvimopan","moa":"Mu opioid receptor","graph1":"Undisclosed","graph2":"Phase II","graph3":"Hartford Hospital","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Hartford Hospital \/ Merck & Co","highestDevelopmentStatusID":"8","companyTruncated":"Hartford Hospital \/ Merck & Co"},{"orgOrder":0,"company":"Brigham and Women's Hospital","sponsor":"Merck & Co","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2017","type":"Inapplicable","leadProduct":"Alvimopan","moa":"Mu opioid receptor","graph1":"Oncology","graph2":"Phase III","graph3":"Brigham and Women's Hospital","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Brigham and Women's Hospital \/ Merck & Co","highestDevelopmentStatusID":"10","companyTruncated":"Brigham and Women's Hospital \/ Merck & Co"},{"orgOrder":0,"company":"University of Virginia","sponsor":"Merck & Co","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"U.S.A","productType":"Miscellaneous","year":"2016","type":"Inapplicable","leadProduct":"Alvimopan","moa":"Mu opioid receptor","graph1":"Gastroenterology","graph2":"Phase IV","graph3":"University of Virginia","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"University of Virginia \/ Merck & Co","highestDevelopmentStatusID":"11","companyTruncated":"University of Virginia \/ Merck & Co"},{"orgOrder":0,"company":"Medical College of Wisconsin","sponsor":"Merck & Co","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"U.S.A","productType":"Miscellaneous","year":"2015","type":"Inapplicable","leadProduct":"Alvimopan","moa":"Mu opioid receptor","graph1":"Gastroenterology","graph2":"Undisclosed","graph3":"Medical College of Wisconsin","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Medical College of Wisconsin \/ Merck & Co","highestDevelopmentStatusID":"1","companyTruncated":"Medical College of Wisconsin \/ Merck & Co"},{"orgOrder":0,"company":"University of Puerto Rico","sponsor":"Merck & Co","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"","productType":"Miscellaneous","year":"2017","type":"Inapplicable","leadProduct":"Alvimopan","moa":"Mu opioid receptor","graph1":"Undisclosed","graph2":"Phase IV","graph3":"University of Puerto Rico","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"University of Puerto Rico \/ Merck & Co","highestDevelopmentStatusID":"11","companyTruncated":"University of Puerto Rico \/ Merck & Co"},{"orgOrder":0,"company":"Merck & Co","sponsor":"Jamie N. Bakkum-Gamez","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2012","type":"Inapplicable","leadProduct":"Alvimopan","moa":"Mu opioid receptor","graph1":"Oncology","graph2":"Phase III","graph3":"Merck & Co","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Merck & Co \/ Jamie N. Bakkum-Gamez","highestDevelopmentStatusID":"10","companyTruncated":"Merck & Co \/ Jamie N. Bakkum-Gamez"},{"orgOrder":0,"company":"Merck & Co","sponsor":"Sharon Stein","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"U.S.A","productType":"Miscellaneous","year":"2016","type":"Inapplicable","leadProduct":"Alvimopan","moa":"Mu opioid receptor","graph1":"Gastroenterology","graph2":"Phase III","graph3":"Merck & Co","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Merck & Co \/ Sharon Stein","highestDevelopmentStatusID":"10","companyTruncated":"Merck & Co \/ Sharon Stein"}]

Find Clinical Drug Pipeline Developments & Deals for Alvimopan Dihydrate

Menu
Xls
Filters Filter
×
FILTER:
filter
Company Name
    filter

    Year

      filter

      DEALS // DEV.

        filter

        Country

          filter
          Sponsor
            filter

            Therapeutic Area

              filter

              Study Phase

                filter

                Deal Type

                  filter

                  Product Type

                    filter

                    Dosage Form

                      filter

                      Lead Product

                        filter

                        Target

                          Loading...

                          Therapeutic Area by Lead Product

                          Study Phase by Lead Product

                          Company by Lead Product

                          Top Deals by Deal Size (USD bn)

                          01

                          Brigham and Women's Hospital

                          Country arrow
                          Neuroscience
                          Not Confirmed

                          Brigham and Women's Hospital

                          Country arrow
                          Neuroscience
                          Not Confirmed

                          Details : Alvimopan is a Other Small Molecule drug candidate, which is currently being evaluated in phase III clinical studies for the treatment of Urinary Bladder Neoplasms.

                          Product Name : Undisclosed

                          Product Type : Miscellaneous

                          Upfront Cash : Inapplicable

                          July 13, 2017

                          Lead Product(s) : Alvimopan

                          Therapeutic Area : Oncology

                          Highest Development Status : Phase III

                          Sponsor : Merck & Co

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          02

                          University of Puerto Rico

                          Country arrow
                          Neuroscience
                          Not Confirmed

                          University of Puerto Rico

                          Country arrow
                          Neuroscience
                          Not Confirmed

                          Details : Alvimopan is a Other Small Molecule drug candidate, which is currently being evaluated in phase IV clinical studies for the treatment of undefined medical condition.

                          Product Name : Undisclosed

                          Product Type : Miscellaneous

                          Upfront Cash : Inapplicable

                          March 03, 2017

                          Lead Product(s) : Alvimopan

                          Therapeutic Area : Undisclosed

                          Highest Development Status : Phase IV

                          Sponsor : Merck & Co

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          03

                          University of Virginia

                          Country arrow
                          Neuroscience
                          Not Confirmed

                          University of Virginia

                          Country arrow
                          Neuroscience
                          Not Confirmed

                          Details : Alvimopan is a Other Small Molecule drug candidate, which is currently being evaluated in phase IV clinical studies for the treatment of Constipation.

                          Product Name : Undisclosed

                          Product Type : Miscellaneous

                          Upfront Cash : Inapplicable

                          June 02, 2016

                          Lead Product(s) : Alvimopan

                          Therapeutic Area : Gastroenterology

                          Highest Development Status : Phase IV

                          Sponsor : Merck & Co

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          04

                          Neuroscience
                          Not Confirmed
                          Neuroscience
                          Not Confirmed

                          Details : Alvimopan is a Other Small Molecule drug candidate, which is currently being evaluated in phase III clinical studies for the treatment of Ileus.

                          Product Name : Undisclosed

                          Product Type : Miscellaneous

                          Upfront Cash : Inapplicable

                          April 18, 2016

                          Lead Product(s) : Alvimopan

                          Therapeutic Area : Gastroenterology

                          Highest Development Status : Phase III

                          Sponsor : Sharon Stein

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          05

                          Medical College of Wisconsin

                          Country arrow
                          Neuroscience
                          Not Confirmed

                          Medical College of Wisconsin

                          Country arrow
                          Neuroscience
                          Not Confirmed

                          Details : Alvimopan is a Other Small Molecule drug candidate, which is currently being evaluated in clinical studies for the treatment of Hernia, Ventral.

                          Product Name : Undisclosed

                          Product Type : Miscellaneous

                          Upfront Cash : Inapplicable

                          March 05, 2015

                          Lead Product(s) : Alvimopan

                          Therapeutic Area : Gastroenterology

                          Highest Development Status : Undisclosed

                          Sponsor : Merck & Co

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          06

                          Neuroscience
                          Not Confirmed
                          Neuroscience
                          Not Confirmed

                          Details : Alvimopan is a Other Small Molecule drug candidate, which is currently being evaluated in phase III clinical studies for the treatment of Ovarian Neoplasms.

                          Product Name : Undisclosed

                          Product Type : Miscellaneous

                          Upfront Cash : Inapplicable

                          October 11, 2012

                          Lead Product(s) : Alvimopan

                          Therapeutic Area : Oncology

                          Highest Development Status : Phase III

                          Sponsor : Jamie N. Bakkum-Gamez

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          07

                          Hartford Hospital

                          Country arrow
                          Neuroscience
                          Not Confirmed

                          Hartford Hospital

                          Country arrow
                          Neuroscience
                          Not Confirmed

                          Details : Alvimopan is a Other Small Molecule drug candidate, which is currently being evaluated in phase II clinical studies for the treatment of undefined medical condition.

                          Product Name : Undisclosed

                          Product Type : Miscellaneous

                          Upfront Cash : Inapplicable

                          December 13, 2010

                          Lead Product(s) : Alvimopan

                          Therapeutic Area : Undisclosed

                          Highest Development Status : Phase II

                          Sponsor : Merck & Co

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank